Evaluation of the QuantiFERON SARS-CoV-2 interferon-ɣ release assay in mRNA-1273 vaccinated health care workers

•44 % of vaccinees had INF-ɣ levels above 015 IU/mL in response to stimulation.•100 % of vaccinees showed INF-ɣ levels above 0015 IU/mL in response to stimulation.•More studies are needed to set an appropriate cut-off for this convenient assay. Current studies focus on cellular and humoral immunity...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of virological methods Ročník 298; s. 114295
Hlavní autori: Krüttgen, Alexander, Klingel, Hanna, Haase, Gerhard, Haefner, Helga, Imöhl, Matthias, Kleines, Michael
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Netherlands Elsevier B.V 01.12.2021
Published by Elsevier B.V
Predmet:
2019-nCoV Vaccine mRNA-1273
Antibodies, Viral
cell-mediated immunity
Cellular immunity
COVID-19
COVID-19 Vaccines
Health Personnel
health services
hepatitis B
Humans
humoral immunity
Interferon-gamma Release Tests
medicine
peptides
RNA, Messenger - genetics
SARS-CoV-2
Serology
Severe acute respiratory syndrome coronavirus 2
Vaccination
vaccines
COVID-19
SARS-CoV-2
Cellular immunity
Serology
Vaccination
ISSN:0166-0934, 1879-0984, 1879-0984
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract •44 % of vaccinees had INF-ɣ levels above 015 IU/mL in response to stimulation.•100 % of vaccinees showed INF-ɣ levels above 0015 IU/mL in response to stimulation.•More studies are needed to set an appropriate cut-off for this convenient assay. Current studies focus on cellular and humoral immunity induced by novel SARS-CoV-2 vaccines. Non-responders to vaccinations are not uncommonly encountered in clinical medicine (e.g. in the field of hepatitis B). Whereas vaccine-induced humoral immunity against SARS-CoV-2 is compromised by emerging Variants of Concern (VOCs), cellular immunity against SARS-CoV-2 is emerging as resilient against VOCs. Thus commercially available test kits for diagnostic laboratories designed to evaluate cellular immune responses to SARS-CoV-2 are urgently needed. Here we evaluated the novel QuantiFERON SARS-CoV-2 assay (Qiagen) measuring INF-ɣ release induced by two spike-derived peptide pools (Ag1 and Ag2) in a cohort of health care workers vaccinated with the mRNA-1273 vaccine and confirmed humoral response. Our study indicates the usefulness of this novel assay for routine laboratories to evaluate cellular immunity against SARS-CoV-2 in response to mRNA-1273 vaccination.
AbstractList Current studies focus on cellular and humoral immunity induced by novel SARS-CoV-2 vaccines. Non-responders to vaccinations are not uncommonly encountered in clinical medicine (e.g. in the field of hepatitis B). Whereas vaccine-induced humoral immunity against SARS-CoV-2 is compromised by emerging Variants of Concern (VOCs), cellular immunity against SARS-CoV-2 is emerging as resilient against VOCs. Thus commercially available test kits for diagnostic laboratories designed to evaluate cellular immune responses to SARS-CoV-2 are urgently needed. Here we evaluated the novel QuantiFERON SARS-CoV-2 assay (Qiagen) measuring INF-ɣ release induced by two spike-derived peptide pools (Ag1 and Ag2) in a cohort of health care workers vaccinated with the mRNA-1273 vaccine and confirmed humoral response. Our study indicates the usefulness of this novel assay for routine laboratories to evaluate cellular immunity against SARS-CoV-2 in response to mRNA-1273 vaccination.
Current studies focus on cellular and humoral immunity induced by novel SARS-CoV-2 vaccines. Non-responders to vaccinations are not uncommonly encountered in clinical medicine (e.g. in the field of hepatitis B). Whereas vaccine-induced humoral immunity against SARS-CoV-2 is compromised by emerging Variants of Concern (VOCs), cellular immunity against SARS-CoV-2 is emerging as resilient against VOCs. Thus commercially available test kits for diagnostic laboratories designed to evaluate cellular immune responses to SARS-CoV-2 are urgently needed. Here we evaluated the novel QuantiFERON SARS-CoV-2 assay (Qiagen) measuring INF-ɣ release induced by two spike-derived peptide pools (Ag1 and Ag2) in a cohort of health care workers vaccinated with the mRNA-1273 vaccine and confirmed humoral response. Our study indicates the usefulness of this novel assay for routine laboratories to evaluate cellular immunity against SARS-CoV-2 in response to mRNA-1273 vaccination.Current studies focus on cellular and humoral immunity induced by novel SARS-CoV-2 vaccines. Non-responders to vaccinations are not uncommonly encountered in clinical medicine (e.g. in the field of hepatitis B). Whereas vaccine-induced humoral immunity against SARS-CoV-2 is compromised by emerging Variants of Concern (VOCs), cellular immunity against SARS-CoV-2 is emerging as resilient against VOCs. Thus commercially available test kits for diagnostic laboratories designed to evaluate cellular immune responses to SARS-CoV-2 are urgently needed. Here we evaluated the novel QuantiFERON SARS-CoV-2 assay (Qiagen) measuring INF-ɣ release induced by two spike-derived peptide pools (Ag1 and Ag2) in a cohort of health care workers vaccinated with the mRNA-1273 vaccine and confirmed humoral response. Our study indicates the usefulness of this novel assay for routine laboratories to evaluate cellular immunity against SARS-CoV-2 in response to mRNA-1273 vaccination.
•44 % of vaccinees had INF-ɣ levels above 015 IU/mL in response to stimulation.•100 % of vaccinees showed INF-ɣ levels above 0015 IU/mL in response to stimulation.•More studies are needed to set an appropriate cut-off for this convenient assay. Current studies focus on cellular and humoral immunity induced by novel SARS-CoV-2 vaccines. Non-responders to vaccinations are not uncommonly encountered in clinical medicine (e.g. in the field of hepatitis B). Whereas vaccine-induced humoral immunity against SARS-CoV-2 is compromised by emerging Variants of Concern (VOCs), cellular immunity against SARS-CoV-2 is emerging as resilient against VOCs. Thus commercially available test kits for diagnostic laboratories designed to evaluate cellular immune responses to SARS-CoV-2 are urgently needed. Here we evaluated the novel QuantiFERON SARS-CoV-2 assay (Qiagen) measuring INF-ɣ release induced by two spike-derived peptide pools (Ag1 and Ag2) in a cohort of health care workers vaccinated with the mRNA-1273 vaccine and confirmed humoral response. Our study indicates the usefulness of this novel assay for routine laboratories to evaluate cellular immunity against SARS-CoV-2 in response to mRNA-1273 vaccination.
ArticleNumber 114295
Author Imöhl, Matthias
Klingel, Hanna
Kleines, Michael
Haase, Gerhard
Krüttgen, Alexander
Haefner, Helga
Author_xml – sequence: 1
  givenname: Alexander
  orcidid: 0000-0002-7157-8454
  surname: Krüttgen
  fullname: Krüttgen, Alexander
  email: akruettgen@ukaachen.de
– sequence: 2
  givenname: Hanna
  surname: Klingel
  fullname: Klingel, Hanna
– sequence: 3
  givenname: Gerhard
  surname: Haase
  fullname: Haase, Gerhard
– sequence: 4
  givenname: Helga
  surname: Haefner
  fullname: Haefner, Helga
– sequence: 5
  givenname: Matthias
  surname: Imöhl
  fullname: Imöhl, Matthias
– sequence: 6
  givenname: Michael
  surname: Kleines
  fullname: Kleines, Michael
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34555429$$D View this record in MEDLINE/PubMed
BookMark eNqFkd9u0zAUhy00xLrBK0y-5CbFf2InkRCiqjpAmjbRAbeW45xQl8QuthO059nT7K3I6DYBN72ypfP9fjpH3wk6ct4BQmeUzCmh8s12vh1t8D2kOSOMzinNWSWeoRktiyojVZkfodkEyunP82N0EuOWECIKzl-gY54LIabADO1Wo-4Gnax32Lc4bQB_HrRL9ny1vrrE14v1dbb03zKGrUsQWgjeZXe3OEAHOgLWMeqbaYb79eUio6zgeNTGWKcTNHgDuksbbHQA_MuHHxDiS_S81V2EVw_vKfp6vvqy_JhdXH34tFxcZCYvhcgqqWtZ1yCFYbqhhkhCdE1oU9CylmVLClaQoqrrXEhBSVvxumg5rSXkjDdS81P0bt-7G-oeGgMuBd2pXbC9DjfKa6v-nTi7Ud_9qMpcMCryqeD1Q0HwPweISfU2Gug67cAPUTHJpWSsksVhVBRS5hXjfELP_l7raZ9HIxMg94AJPsYA7RNCibpXr7bqUb26V6_26qfg2_-CxqY_YqfzbHc4_n4fh0nKaCGoaCw4A40NYJJqvD1U8Rtdys6C
CitedBy_id crossref_primary_10_3390_diagnostics13172722
crossref_primary_10_1128_spectrum_02495_21
crossref_primary_10_17116_labs20241303131
crossref_primary_10_3389_fimmu_2022_960001
crossref_primary_10_1128_spectrum_01402_21
crossref_primary_10_1371_journal_pone_0303244
crossref_primary_10_3390_vaccines12020174
crossref_primary_10_3390_vaccines10071068
crossref_primary_10_3390_diagnostics13243688
crossref_primary_10_1007_s12026_024_09570_w
crossref_primary_10_3389_fimmu_2024_1397052
crossref_primary_10_1016_j_jviromet_2022_114472
crossref_primary_10_1016_j_ijid_2022_07_049
crossref_primary_10_3390_diagnostics12061401
crossref_primary_10_1016_j_clim_2022_108979
crossref_primary_10_1093_cei_uxad027
crossref_primary_10_1371_journal_pone_0285728
crossref_primary_10_1016_j_ebiom_2023_104886
crossref_primary_10_3390_v15051179
crossref_primary_10_1016_j_imbio_2023_152755
crossref_primary_10_3390_jcm12093172
crossref_primary_10_1111_1744_9987_70066
crossref_primary_10_1055_s_0042_1748170
crossref_primary_10_3389_fimmu_2023_1179620
crossref_primary_10_3389_fimmu_2022_1049188
crossref_primary_10_1016_j_clim_2023_109342
crossref_primary_10_3390_vaccines10071031
crossref_primary_10_3389_fimmu_2023_1120556
crossref_primary_10_1146_annurev_immunol_101721_061120
crossref_primary_10_3390_vaccines10081189
crossref_primary_10_3390_vaccines10040556
crossref_primary_10_1007_s10096_022_04422_7
crossref_primary_10_1002_eji_202249794
Cites_doi 10.3201/eid2701.203611
10.1016/j.jinf.2021.03.010
10.1056/NEJMoa2001017
10.1016/j.jviromet.2020.113978
10.1016/j.jiac.2021.08.016
10.1038/s41586-020-2012-7
10.4161/hv.6.9.12420
10.1056/NEJMoa2028436
10.1172/JCI149335
10.1093/ndt/gfab064
10.1016/j.jviromet.2021.114122
10.1016/j.tube.2017.11.014
10.3389/fimmu.2021.676932
10.1038/s41586-021-03653-6
10.1016/j.humimm.2021.05.003
10.1097/MD.0000000000015228
ContentType Journal Article
Copyright 2021 Elsevier B.V.
Copyright © 2021. Published by Elsevier B.V.
2021 Published by Elsevier B.V. 2021
Copyright_xml – notice: 2021 Elsevier B.V.
– notice: Copyright © 2021. Published by Elsevier B.V.
– notice: 2021 Published by Elsevier B.V. 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
5PM
DOI 10.1016/j.jviromet.2021.114295
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList
AGRICOLA
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
Medicine
EISSN 1879-0984
EndPage 114295
ExternalDocumentID PMC8452154
34555429
10_1016_j_jviromet_2021_114295
S0166093421002342
Genre Journal Article
GroupedDBID ---
--K
--M
.GJ
.~1
0R~
1B1
1RT
1~.
1~5
29L
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
AAAJQ
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AAXUO
ABBQC
ABFNM
ABFRF
ABJNI
ABLVK
ABMAC
ABMZM
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
ADMUD
AEBSH
AEFWE
AEKER
AENEX
AFFNX
AFKWA
AFTJW
AFXIZ
AGEKW
AGHFR
AGUBO
AGYEJ
AHHHB
AI.
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CJTIS
CNWQP
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEJ
HMG
HMK
HMO
HVGLF
HZ~
IH2
IHE
J1W
K-O
KOM
L7B
LCYCR
LUGTX
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SES
SEW
SIN
SPCBC
SSH
SSI
SSZ
T5K
VH1
WUQ
XFK
Y6R
ZGI
~G-
~KM
9DU
AAHBH
AATTM
AAXKI
AAYWO
AAYXX
ABWVN
ACIEU
ACLOT
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGQPQ
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
CITATION
EFKBS
~HD
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
5PM
ID FETCH-LOGICAL-c4855-96ab6bbe65c2ad1c0600ab01d718b68f0727079bb456510f93b7f31b6e423d6a3
ISSN 0166-0934
1879-0984
IngestDate Tue Sep 30 16:54:56 EDT 2025
Sat Sep 27 21:14:35 EDT 2025
Thu Oct 02 08:23:14 EDT 2025
Thu Apr 03 07:08:38 EDT 2025
Tue Nov 18 21:36:36 EST 2025
Sat Nov 29 07:26:10 EST 2025
Fri Feb 23 02:42:28 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19
SARS-CoV-2
Cellular immunity
Serology
Vaccination
Language English
License Copyright © 2021. Published by Elsevier B.V.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4855-96ab6bbe65c2ad1c0600ab01d718b68f0727079bb456510f93b7f31b6e423d6a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-7157-8454
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8452154
PMID 34555429
PQID 2576649233
PQPubID 23479
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8452154
proquest_miscellaneous_2636622967
proquest_miscellaneous_2576649233
pubmed_primary_34555429
crossref_primary_10_1016_j_jviromet_2021_114295
crossref_citationtrail_10_1016_j_jviromet_2021_114295
elsevier_sciencedirect_doi_10_1016_j_jviromet_2021_114295
PublicationCentury 2000
PublicationDate 2021-12-01
PublicationDateYYYYMMDD 2021-12-01
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-01
  day: 01
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Journal of virological methods
PublicationTitleAlternate J Virol Methods
PublicationYear 2021
Publisher Elsevier B.V
Published by Elsevier B.V
Publisher_xml – name: Elsevier B.V
– name: Published by Elsevier B.V
References Ruan, Guo, Liang, Xu, Niu (bib0050) 2019; 98
Sahin, Muik, Vogler, Derhovanessian, Kranz, Vormehr (bib0055) 2021
Zhu, Zhang, Wang, Li, Yang, Song (bib0085) 2020; 382
Heininger, Gambon, Gruber, Margelli (bib0020) 2010; 6
Pieterman, Liqui Lung, Verbon, Bax, Ang, Berkhout (bib0045) 2018; 108
Krüttgen, Cornelissen, Dreher, Hornef, Imöhl, Kleines (bib0030) 2021; 287
Tarke, Sidney, Methot, Zhang, Dan, Goodwin (bib0065) 2021
Zhou, Yang, Wang, Hu, Zhang, Zhang (bib0080) 2020; 579
Townsend, Dyer, Naughton, Kiersey, Holden, Gardiner (bib0070) 2021; 12
Müller, Girl, von Buttlar, Dobler, Wölfel (bib0035) 2021; 292
Murray, McIntosh, Atkinson, Mahungu, Wright, Chatterton (bib0040) 2021; 82
Saulle, Vicentini, Clerici, Biasin (bib0060) 2021; 82
Gallais, Velay, Nazon, Wendling, Partisani, Sibilia (bib0015) 2021; 27
Fukushima, Kubo, Akagi, Miyashita, Kondo, Ehara (bib0010) 2021
Anderson, Rouphael, Widge, Jackson, Roberts, Makhene (bib0005) 2020; 383
Woldemeskel, Garliss, Blankson (bib0075) 2021; 131
Kronbichler, Anders, Fernandez-Juárez, Floege, Goumenos, Segelmark (bib0025) 2021
Murray (10.1016/j.jviromet.2021.114295_bib0040) 2021; 82
Zhou (10.1016/j.jviromet.2021.114295_bib0080) 2020; 579
Saulle (10.1016/j.jviromet.2021.114295_bib0060) 2021; 82
Zhu (10.1016/j.jviromet.2021.114295_bib0085) 2020; 382
Ruan (10.1016/j.jviromet.2021.114295_bib0050) 2019; 98
Townsend (10.1016/j.jviromet.2021.114295_bib0070) 2021; 12
Anderson (10.1016/j.jviromet.2021.114295_bib0005) 2020; 383
Müller (10.1016/j.jviromet.2021.114295_bib0035) 2021; 292
Tarke (10.1016/j.jviromet.2021.114295_bib0065) 2021
Gallais (10.1016/j.jviromet.2021.114295_bib0015) 2021; 27
Pieterman (10.1016/j.jviromet.2021.114295_bib0045) 2018; 108
Sahin (10.1016/j.jviromet.2021.114295_bib0055) 2021
Fukushima (10.1016/j.jviromet.2021.114295_bib0010) 2021
Heininger (10.1016/j.jviromet.2021.114295_bib0020) 2010; 6
Woldemeskel (10.1016/j.jviromet.2021.114295_bib0075) 2021; 131
Krüttgen (10.1016/j.jviromet.2021.114295_bib0030) 2021; 287
Kronbichler (10.1016/j.jviromet.2021.114295_bib0025) 2021
35065949 - J Virol Methods. 2022 Apr;302:114472. doi: 10.1016/j.jviromet.2022.114472
References_xml – volume: 82
  start-page: 170
  year: 2021
  end-page: 177
  ident: bib0040
  article-title: Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay
  publication-title: J. Infect.
– year: 2021
  ident: bib0055
  article-title: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
  publication-title: Nature
– volume: 287
  year: 2021
  ident: bib0030
  article-title: Determination of SARS-CoV-2 antibodies with assays from Diasorin, Roche and IDvet
  publication-title: J. Virol. Methods
– volume: 579
  start-page: 270
  year: 2020
  end-page: 273
  ident: bib0080
  article-title: A pneumonia outbreak associated with a new coronavirus of probable bat origin
  publication-title: Nature
– volume: 98
  year: 2019
  ident: bib0050
  article-title: Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation: a PRISMA-compliant article
  publication-title: Medicine (Baltimore)
– volume: 383
  start-page: 2427
  year: 2020
  end-page: 2438
  ident: bib0005
  article-title: Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
  publication-title: N. Engl. J. Med.
– volume: 108
  start-page: 136
  year: 2018
  end-page: 142
  ident: bib0045
  article-title: A multicentre verification study of the QuantiFERON(®)-TB Gold Plus assay
  publication-title: Tuberculosis (Edinb)
– volume: 131
  year: 2021
  ident: bib0075
  article-title: SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63
  publication-title: J. Clin. Invest.
– volume: 382
  start-page: 727
  year: 2020
  end-page: 733
  ident: bib0085
  article-title: A Novel Coronavirus from Patients with Pneumonia in China, 2019
  publication-title: N. Engl. J. Med.
– volume: 292
  year: 2021
  ident: bib0035
  article-title: Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2
  publication-title: J. Virol. Methods
– volume: 82
  start-page: 551
  year: 2021
  end-page: 560
  ident: bib0060
  article-title: Antigen presentation in SARS-CoV-2 infection: the role of class I HLA and ERAP polymorphisms
  publication-title: Hum. Immunol.
– volume: 27
  start-page: 113
  year: 2021
  end-page: 121
  ident: bib0015
  article-title: Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion
  publication-title: France. Emerging Infectious Dis.
– volume: 6
  year: 2010
  ident: bib0020
  article-title: Successful hepatitis B immunization in non- and low responding health care workers
  publication-title: Hum. Vaccin.
– year: 2021
  ident: bib0025
  article-title: Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases
  publication-title: Nephrol. Dial. Transplant.
– year: 2021
  ident: bib0065
  article-title: Negligible impact of SARS-CoV-2 variants on CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and vaccinees
  publication-title: bioRxiv
– year: 2021
  ident: bib0010
  article-title: Clinical evaluation of QuantiFERON®-TB Gold plus directly compared with QuantiFERON®-TB Gold in-tube and T-Spot®.TB for active pulmonary tuberculosis in the elderly
  publication-title: J. Infect. Chemother.
– volume: 12
  year: 2021
  ident: bib0070
  article-title: Longitudinal analysis of COVID-19 patients shows age-associated t cell changes independent of ongoing ill-health
  publication-title: Front. Immunol.
– volume: 27
  start-page: 113
  issue: 1
  year: 2021
  ident: 10.1016/j.jviromet.2021.114295_bib0015
  article-title: Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion
  publication-title: France. Emerging Infectious Dis.
  doi: 10.3201/eid2701.203611
– volume: 82
  start-page: 170
  issue: 5
  year: 2021
  ident: 10.1016/j.jviromet.2021.114295_bib0040
  article-title: Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay
  publication-title: J. Infect.
  doi: 10.1016/j.jinf.2021.03.010
– volume: 382
  start-page: 727
  issue: 8
  year: 2020
  ident: 10.1016/j.jviromet.2021.114295_bib0085
  article-title: A Novel Coronavirus from Patients with Pneumonia in China, 2019
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2001017
– year: 2021
  ident: 10.1016/j.jviromet.2021.114295_bib0065
  article-title: Negligible impact of SARS-CoV-2 variants on CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and vaccinees
  publication-title: bioRxiv
– volume: 287
  year: 2021
  ident: 10.1016/j.jviromet.2021.114295_bib0030
  article-title: Determination of SARS-CoV-2 antibodies with assays from Diasorin, Roche and IDvet
  publication-title: J. Virol. Methods
  doi: 10.1016/j.jviromet.2020.113978
– year: 2021
  ident: 10.1016/j.jviromet.2021.114295_bib0010
  article-title: Clinical evaluation of QuantiFERON®-TB Gold plus directly compared with QuantiFERON®-TB Gold in-tube and T-Spot®.TB for active pulmonary tuberculosis in the elderly
  publication-title: J. Infect. Chemother.
  doi: 10.1016/j.jiac.2021.08.016
– volume: 579
  start-page: 270
  issue: 7798
  year: 2020
  ident: 10.1016/j.jviromet.2021.114295_bib0080
  article-title: A pneumonia outbreak associated with a new coronavirus of probable bat origin
  publication-title: Nature
  doi: 10.1038/s41586-020-2012-7
– volume: 6
  issue: 9
  year: 2010
  ident: 10.1016/j.jviromet.2021.114295_bib0020
  article-title: Successful hepatitis B immunization in non- and low responding health care workers
  publication-title: Hum. Vaccin.
  doi: 10.4161/hv.6.9.12420
– volume: 383
  start-page: 2427
  issue: 25
  year: 2020
  ident: 10.1016/j.jviromet.2021.114295_bib0005
  article-title: Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2028436
– volume: 131
  issue: 10
  year: 2021
  ident: 10.1016/j.jviromet.2021.114295_bib0075
  article-title: SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI149335
– year: 2021
  ident: 10.1016/j.jviromet.2021.114295_bib0025
  article-title: Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases
  publication-title: Nephrol. Dial. Transplant.
  doi: 10.1093/ndt/gfab064
– volume: 292
  year: 2021
  ident: 10.1016/j.jviromet.2021.114295_bib0035
  article-title: Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2
  publication-title: J. Virol. Methods
  doi: 10.1016/j.jviromet.2021.114122
– volume: 108
  start-page: 136
  year: 2018
  ident: 10.1016/j.jviromet.2021.114295_bib0045
  article-title: A multicentre verification study of the QuantiFERON(®)-TB Gold Plus assay
  publication-title: Tuberculosis (Edinb)
  doi: 10.1016/j.tube.2017.11.014
– volume: 12
  year: 2021
  ident: 10.1016/j.jviromet.2021.114295_bib0070
  article-title: Longitudinal analysis of COVID-19 patients shows age-associated t cell changes independent of ongoing ill-health
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.676932
– year: 2021
  ident: 10.1016/j.jviromet.2021.114295_bib0055
  article-title: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
  publication-title: Nature
  doi: 10.1038/s41586-021-03653-6
– volume: 82
  start-page: 551
  issue: 8
  year: 2021
  ident: 10.1016/j.jviromet.2021.114295_bib0060
  article-title: Antigen presentation in SARS-CoV-2 infection: the role of class I HLA and ERAP polymorphisms
  publication-title: Hum. Immunol.
  doi: 10.1016/j.humimm.2021.05.003
– volume: 98
  issue: 16
  year: 2019
  ident: 10.1016/j.jviromet.2021.114295_bib0050
  article-title: Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation: a PRISMA-compliant article
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000015228
– reference: 35065949 - J Virol Methods. 2022 Apr;302:114472. doi: 10.1016/j.jviromet.2022.114472
SSID ssj0005733
Score 2.5137632
Snippet •44 % of vaccinees had INF-ɣ levels above 015 IU/mL in response to stimulation.•100 % of vaccinees showed INF-ɣ levels above 0015 IU/mL in response to...
Current studies focus on cellular and humoral immunity induced by novel SARS-CoV-2 vaccines. Non-responders to vaccinations are not uncommonly encountered in...
SourceID pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 114295
SubjectTerms 2019-nCoV Vaccine mRNA-1273
Antibodies, Viral
cell-mediated immunity
Cellular immunity
COVID-19
COVID-19 Vaccines
Health Personnel
health services
hepatitis B
Humans
humoral immunity
Interferon-gamma Release Tests
medicine
peptides
RNA, Messenger - genetics
SARS-CoV-2
Serology
Severe acute respiratory syndrome coronavirus 2
Vaccination
vaccines
Title Evaluation of the QuantiFERON SARS-CoV-2 interferon-ɣ release assay in mRNA-1273 vaccinated health care workers
URI https://dx.doi.org/10.1016/j.jviromet.2021.114295
https://www.ncbi.nlm.nih.gov/pubmed/34555429
https://www.proquest.com/docview/2576649233
https://www.proquest.com/docview/2636622967
https://pubmed.ncbi.nlm.nih.gov/PMC8452154
Volume 298
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals 2021
  customDbUrl:
  eissn: 1879-0984
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0005733
  issn: 0166-0934
  databaseCode: AIEXJ
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DRAvCMatXCYjMV4qb4mdOPFjqVoGKh103dS3yEmT0WqkpWur8Sf4E_wa_hXHsXMZFDYeeImqJG4u58vxZ_uc7yD0knER2Z7PiR1JnzjQCRDJhSBUUD8KKY95FkRz0vV6PX84FB9qtW95LszqzEtT_-JCzP6rqWEfGFulzv6DuYs_hR3wG4wOWzA7bK9l-Hah352v_39cwusbd9r9w17jqNk_Iq3pCaGZUsQ8iefTlOy2xG6TZQVUoFdrAKGWWT7g536vSWzgHo2VjKJxKhU_1amTmaZ1VmnGxNCvobgqhy73rbpUdbl0lC3Rv24tFqfa8RWZNsUZKlFexxAcyDSVpa-Uuhjkm3ieawLo_XFisnegLz2V1fkMaldiQ8wUJ-fEEmaK0_hoKvzGTOkaU-GStZ5fT0JM9ibq0eCR9tR_mxZlX5ev7_cOg85xtxsM2sPBq9kXoqqQqdV6U5JlA21RzxXgJbeab9vDd2XQkMeYVovX91jJOV9_6T_Rnd-HM79G5VZozuAuumOMh5saV_dQLU630U1dsfTrNrr13sRi3EezEmh4mmAAGq4ADZdAwxWg_fiODchwBjI4hguQ4RJkWIMMK5BhA7IH6LjTHrQOiKnfQSIlOUQElyEPw5i7EZUjO7KAXMvQskfAh0LuJxZwZ8sTYahGFbaVCBZ6CbNDHgPHH3HJHqLNdJrGjxFmXMJI2FFKSJGjVC55JKjFYt-S7og7bh25-WsOIiNur2qsnAV5FOMkyM0TKPME2jx1tF-0m2l5lytbiNyKgSGpmnwGgMQr277IzR6AF1dLczKNp8vzQA37udJKZH85hzPOKRXcq6NHGirFPTPHdVXluTryLoGoOEGpyF8-ko4_ZWryvgMM3nWeXOO6T9Ht8ot9hjYX82X8HN2IVovx-XwHbXhDf8d8MT8BeQ_lpw
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+the+QuantiFERON+SARS-CoV-2+interferon-%C9%A3+release+assay+in+mRNA-1273+vaccinated+health+care+workers&rft.jtitle=Journal+of+virological+methods&rft.au=Kr%C3%BCttgen%2C+Alexander&rft.au=Klingel%2C+Hanna&rft.au=Haase%2C+Gerhard&rft.au=Haefner%2C+Helga&rft.date=2021-12-01&rft.issn=0166-0934&rft.volume=298+p.114295-&rft_id=info:doi/10.1016%2Fj.jviromet.2021.114295&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0166-0934&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0166-0934&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0166-0934&client=summon